His primary scientific interests are in Immunology, Molecular biology, In vivo, Interleukin 2 and Cytotoxic T cell. His study ties his expertise on Cancer research together with the subject of Immunology. His Molecular biology research includes themes of Affinity label, Alpha, Virology, Genetic enhancement and Cytolysis.
He combines subjects such as Biochemistry, Interferon gamma, Cytotoxicity and Pharmacology with his study of In vivo. His Interleukin 2 study combines topics from a wide range of disciplines, such as Toxicity, Lymphokine, Gastroenterology and Lymphokine-activated killer cell. His Antigen research is multidisciplinary, incorporating elements of Antibody, Monoclonal antibody and Antibody-dependent cell-mediated cytotoxicity.
His primary areas of investigation include Immunology, Cancer research, Immunotherapy, Monoclonal antibody and Interleukin 2. His studies in Immunology integrate themes in fields like Cytotoxic T cell and In vivo. In his research, Bone marrow is intimately related to T cell, which falls under the overarching field of Cancer research.
His Monoclonal antibody research incorporates themes from Receptor and Neuroblastoma. His research in Interleukin 2 intersects with topics in Lymphokine, Lymphokine-activated killer cell and Lymphocyte. His study in Antigen is interdisciplinary in nature, drawing from both Molecular biology and Virology.
Paul M. Sondel mainly investigates Immunotherapy, Cancer research, Neuroblastoma, Internal medicine and Antibody. Paul M. Sondel has begun a study into Immunotherapy, looking into Immune system and Immunology. His work deals with themes such as Alpha and Glycan, which intersect with Immunology.
His study in the field of Melanoma also crosses realms of In situ. His Internal medicine research integrates issues from Gastroenterology, Oncology and Monoclonal. His studies deal with areas such as In vivo, Solid tumor, Pharmacology and Antigen as well as Monoclonal antibody.
The scientist’s investigation covers issues in Internal medicine, Oncology, Immunotherapy, Neuroblastoma and Cancer research. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Monoclonal. His research integrates issues of Clinical trial, Refractory, Dinutuximab, Virus and Pneumonitis in his study of Oncology.
As a part of the same scientific family, Paul M. Sondel mostly works in the field of Immunotherapy, focusing on Antibody and, on occasion, Lipopolysaccharide, Cancer cell, Cytolysis and Cell biology. His Neuroblastoma research incorporates elements of Solid tumor, Monoclonal antibody and Phases of clinical research. His study explores the link between Cancer research and topics such as Immune system that cross with problems in Natural killer cell and In vitro.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens
Robert DeMars;Robert DeMars;Cecile C Chang;Cecile C Chang;Stephen Shaw;Stephen Shaw;Pamela J Reitnauer;Pamela J Reitnauer.
Human Immunology (1984)
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
R. R. Brown;Y. Ozaki;S. P. Datta;Ernest C Borden.
Advances in Experimental Medicine and Biology (1991)
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes.
Joseph M. Carlin;Ernest C. Borden;Paul M. Sondel;Gerald I. Byrne.
Journal of Leukocyte Biology (1989)
Phase I Study of Chimeric Human/Murine Anti–Ganglioside GD2 Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group Study
M. Fevzi Ozkaynak;Paul M. Sondel;Mark D. Krailo;Jacek Gan.
Journal of Clinical Oncology (2000)
A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group
Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan.
Clinical Cancer Research (2006)
Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients
David M. King;Mark R. Albertini;Heidi Schalch;Jacquelyn A. Hank.
Journal of Clinical Oncology (2004)
Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
Jeff A. Sosman;Peter C. Kohler;Jacquelyn Hank;Karen H. Moore.
Journal of the National Cancer Institute (1988)
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
David C. Delgado;Jacquelyn A. Hank;Jill Kolesar;David Lorentzen.
Cancer Research (2010)
Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.
Joel G. Turner;Alexander L. Rakhmilevich;Lyudmila Burdelya;Zane Neal.
Journal of Immunology (2001)
A multigene family on human chromosome 12 encodes natural killer-cell lectins.
Toshio Yabe;Cynthia McSherry;Fritz H. Bach;Paul Fisch.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: